Full Text View
Tabular View
No Study Results Posted
Related Studies
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
This study has been completed.
Study NCT01183013   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on August 16, 2010.   Last Updated on May 15, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus, Type 2
Additional conditions recognized in this trial
Diabetes Mellitus
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
Pioglitazone 15 mg
Pioglitazone 45 mg
Pioglitazone 30 mg
BI 1356 / Pioglitazone 45 mg FDC
BI 1356 / Pioglitazone 30 mg FDC
BI 1356
BI 1356 / Pioglitazone 15 mg FDC
Additional drug interventions recognized in this trial
Pioglitazone
More general drug interventions related to this trial
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services